Hodgkin

Dennis Thompson TUESDAY, July 6, 2023 (HealthDay News) -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin…

Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 heavily pre-treated patients dosed with TT11 Research presented in an oral…

Why did my child get cancer? Clinicians have longed for a way to help answer this question. Doctors knew Hodgkin lymphoma sometimes occurs in families, but why this happens has been a mystery. Scientists at St. Jude Children's Research…

Phase 1b clinical trial (ACTION) designed to evaluate TT11 as a potential second-line therapy TT11, Tessa’s autologous CD30-CAR-T therapy, is also being investigated as a monotherapy in the treatment of relapsed/refractory cHL SINGAPORE,…

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the…

Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating…

Three-fourths of patients with relapsed/refractory Hodgkin lymphoma remained alive without disease progression 3 years after treatment with…